BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 3047333)

  • 1. Randomized trial of observation versus adjuvant therapy with cyclophosphamide, fluorouracil, prednisone with or without tamoxifen following mastectomy in postmenopausal women with node-positive breast cancer.
    Ingle JN; Everson LK; Wieand HS; Martin JK; Votava HJ; Wold LE; Krook JE; Cullinan SA; Paulsen JK; Twito DI
    J Clin Oncol; 1988 Sep; 6(9):1388-96. PubMed ID: 3047333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized trial to evaluate the addition of tamoxifen to cyclophosphamide, 5-fluorouracil, prednisone adjuvant therapy in premenopausal women with node-positive breast cancer.
    Ingle JN; Everson LK; Wieand HS; Cullinan SA; Wold LE; Hagen JB; Martin JK; Krook JE; Fitzgibbons RG; Foley JF
    Cancer; 1989 Apr; 63(7):1257-64. PubMed ID: 2646004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant CMFP versus CMFP plus tamoxifen versus observation alone in postmenopausal, node-positive breast cancer patients: three-year results of an Eastern Cooperative Oncology Group study.
    Taylor SG; Kalish LA; Olson JE; Cummings F; Bennett JM; Falkson G; Tormey DC; Carbone PP
    J Clin Oncol; 1985 Feb; 3(2):144-54. PubMed ID: 3881561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Weight change in women treated with adjuvant therapy or observed following mastectomy for node-positive breast cancer.
    Camoriano JK; Loprinzi CL; Ingle JN; Therneau TM; Krook JE; Veeder MH
    J Clin Oncol; 1990 Aug; 8(8):1327-34. PubMed ID: 2199619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomised trial of chemo-endocrine therapy, endocrine therapy, and mastectomy alone in postmenopausal patients with operable breast cancer and axillary node metastasis.
    Ludwig Breast Cancer Study Group
    Lancet; 1984 Jun; 1(8389):1256-60. PubMed ID: 6144974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized clinical trial of cyclophosphamide, 5-FU, and prednisone with or without tamoxifen in postmenopausal women with advanced breast cancer.
    Krook JE; Ingle JN; Green SJ; Bowman WD; Everson LK; Windschitl HE; Marschke RF; Laurie JA; Cullinan SA; Pfeifle DM
    Cancer Treat Rep; 1985 Apr; 69(4):355-61. PubMed ID: 3888386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Six-year results of the Eastern Cooperative Oncology Group trial of observation versus CMFP versus CMFPT in postmenopausal patients with node-positive breast cancer.
    Taylor SG; Knuiman MW; Sleeper LA; Olson JE; Tormey DC; Gilchrist KW; Falkson G; Rosenthal SN; Carbone PP; Cummings FJ
    J Clin Oncol; 1989 Jul; 7(7):879-89. PubMed ID: 2661734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study.
    Rivkin SE; Green S; Metch B; Cruz AB; Abeloff MD; Jewell WR; Costanzi JJ; Farrar WB; Minton JP; Osborne CK
    J Clin Oncol; 1994 Oct; 12(10):2078-85. PubMed ID: 7931477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant CMFVP versus melphalan for operable breast cancer with positive axillary nodes: 10-year results of a Southwest Oncology Group Study.
    Rivkin SE; Green S; Metch B; Glucksberg H; Gad-el-Mawla N; Constanzi JJ; Hoogstraten B; Athens J; Maloney T; Osborne CK
    J Clin Oncol; 1989 Sep; 7(9):1229-38. PubMed ID: 2671283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant trial of 12 cycles of CMFPT followed by observation or continuous tamoxifen versus four cycles of CMFPT in postmenopausal women with breast cancer: an Eastern Cooperative Oncology Group phase III study.
    Falkson HC; Gray R; Wolberg WH; Gillchrist KW; Harris JE; Tormey DC; Falkson G
    J Clin Oncol; 1990 Apr; 8(4):599-607. PubMed ID: 2179477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new endpoint for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer.
    Gelber RD; Goldhirsch A
    J Clin Oncol; 1986 Dec; 4(12):1772-9. PubMed ID: 3783203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An intergroup study.
    Mansour EG; Gray R; Shatila AH; Osborne CK; Tormey DC; Gilchrist KW; Cooper MR; Falkson G
    N Engl J Med; 1989 Feb; 320(8):485-90. PubMed ID: 2915651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study.
    Rivkin SE; Green SJ; Lew D; Costanzi JJ; Athens JW; Osborne CK; Vaughn CB; Martino S
    Cancer; 2003 Jan; 97(1):21-9. PubMed ID: 12491501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant treatment for early breast cancer: the Ludwig breast cancer studies.
    Goldhirsch A; Gelber R
    NCI Monogr; 1986; (1):55-70. PubMed ID: 3774016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant treatment in operable breast cancer.
    Goldhirsch A
    J Steroid Biochem; 1985 Dec; 23(6B):1155-60. PubMed ID: 3912622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: a report of the National Cancer Institute of Canada Clinical Trials Group. Breast Cancer Site Group.
    Pritchard KI; Paterson AH; Fine S; Paul NA; Zee B; Shepherd LE; Abu-Zahra H; Ragaz J; Knowling M; Levine MN; Verma S; Perrault D; Walde PL; Bramwell VH; Poljicak M; Boyd N; Warr D; Norris BD; Bowman D; Armitage GR; Weizel H; Buckman RA
    J Clin Oncol; 1997 Jun; 15(6):2302-11. PubMed ID: 9196144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant CMFVP versus adjuvant CMFVP plus ovariectomy for premenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study.
    Rivkin SE; Green S; O'Sullivan J; Cruz AB; Abeloff MD; Jewell WR; Costanzi JJ; Farrar WB; Osborne CK
    J Clin Oncol; 1996 Jan; 14(1):46-51. PubMed ID: 8558219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination adjuvant chemotherapy for node-positive breast cancer. Inadequacy of a single perioperative cycle.
    Ludwig Breast Cancer Study Group
    N Engl J Med; 1988 Sep; 319(11):677-83. PubMed ID: 2901037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized clinical trial of CFP versus CMFP in women with metastatic breast cancer.
    Marschke RF; Ingle JN; Schaid DJ; Krook JE; Mailliard JA; Cullinan SA; Pfeifle DM; Votava HJ; Ebbert LP; Windschitl HE
    Cancer; 1989 May; 63(10):1931-7. PubMed ID: 2649221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16.
    Fisher B; Redmond C; Legault-Poisson S; Dimitrov NV; Brown AM; Wickerham DL; Wolmark N; Margolese RG; Bowman D; Glass AG
    J Clin Oncol; 1990 Jun; 8(6):1005-18. PubMed ID: 2189950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.